Business Partnership Announcement

Annovis Bio Partners NeuroRPM for Parkinson's Study

Analysis based on 7 articles · First reported Mar 19, 2026 · Last updated Mar 19, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

This partnership is likely to have a positive impact on Annovis Bio's stock as it enhances the data collection and monitoring capabilities of its Parkinson's study, potentially leading to stronger clinical trial outcomes. NeuroRPM also benefits from increased visibility and adoption of its FDA-cleared AI platform in a significant clinical trial.

Biotechnology Digital Health Pharmaceuticals

Event Summary

Annovis Bio, a biotechnology company, announced a partnership with NeuroRPM, a digital health technology company, to integrate an FDA-cleared artificial intelligence (AI) platform into its ongoing Phase 3 open-label Parkinson's disease study (ANVS-25002). The AI platform will collect movement data to monitor primary Parkinson's symptoms like bradykinesia, tremor, and dyskinesia, serving as a digital biomarker. This initiative aims to strengthen evidence-based monitoring of disease progression and provide insights for future clinical trials. The study, which is testing the investigational oral therapy buntanetap, is currently enrolling participants across 25 sites in the United States. In addition to the digital biomarker, Annovis Bio is also implementing a highly accurate biomarker test for misfolded phosphorylated alpha-synuclein. This combination of cutting-edge digital and biological biomarkers is expected to provide a comprehensive understanding of patients' response to treatment.

Key Actions

100 Annovis Bio partnered with NeuroRPM

90 NeuroRPM implemented AI platform in clinical study Annovis Bio

Entities Involved

stock

Annovis Bio

Annovis Bio announced a partnership with NeuroRPM to integrate an FDA-cleared AI platform into its Parkinson's disease study. This collaboration is expected to enhance data collection and monitoring of disease progression, potentially strengthening the evidence base for its drug candidate, buntanetap.

Importance 100 Sentiment 40

priv

NeuroRPM

NeuroRPM is partnering with Annovis Bio to deploy its FDA-cleared AI platform for monitoring Parkinson's disease symptoms in a clinical trial. This partnership provides a significant opportunity for NeuroRPM to expand the use of its technology in clinical research and potentially in patient care.

Importance 90 Sentiment 40

per

Collaborative Fusion

Collaborative Fusion, CEO of NeuroRPM, commented on the partnership, highlighting the benefits of continuous wearable monitoring for understanding treatment response in real-world settings.

Importance 20 Sentiment 30

per

Cheng Fang

Cheng Fang, Senior Vice President of Research and Development at Annovis Bio, expressed excitement about the collaboration, emphasizing the value of data-driven insights from NeuroRPM's platform.

Importance 20 Sentiment 30

cnt

United States

The ANVS-25002 study is enrolling participants across 25 sites in the United States, indicating the geographical scope of the clinical trial.

Importance 10 Sentiment 0

govactor

United States===Food and Drug Administration

NeuroRPM's AI platform is FDA-cleared, which signifies its regulatory approval for medical device use and adds credibility to the technology.

Importance 10 Sentiment 0

Relationships

Annovis Bio related ↔ NeuroRPM

Collaborative Fusion related ↔ NeuroRPM

Cheng Fang related ↔ Annovis Bio

United States===Food and Drug Administration related ↔ NeuroRPM

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard